These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19135943)

  • 21. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
    Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single-center experience of cytomegalovirus infections in Asian pediatric patients undergoing allogeneic hematopoietic stem cell transplant for leukemia in Singapore.
    Tan PL; Lim LM; Khanlian C; Villegas MS
    Transpl Infect Dis; 2014 Aug; 16(4):556-60. PubMed ID: 24862456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation.
    Kalra A; Williamson T; Daly A; Savoie ML; Stewart DA; Khan F; Storek J
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1654-1663. PubMed ID: 27246372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.
    Nachbaur D; Clausen J; Kircher B
    Eur J Haematol; 2006 May; 76(5):414-9. PubMed ID: 16480430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific donor HLA allotypes as predictors of cytomegalovirus disease risk in acute myeloid leukemia.
    Min GJ; Kim HJ; Kim TG; Hyun YS; Hyun SJ; Baek IC; Yoon SY; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW
    HLA; 2020 Oct; 96(4):445-455. PubMed ID: 32506817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
    Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
    J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus reactivation in pediatric hemopoietic progenitors transplant: a retrospective study on the risk factors and the efficacy of treatment.
    Patel SR; Ridwan RU; Ortín M
    J Pediatr Hematol Oncol; 2005 Aug; 27(8):411-5. PubMed ID: 16096521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
    J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic transplantation for patients with advanced acute leukemia: a single center retrospective study of 92 patients.
    Boiron JM; Lerner D; Pigneux A; Fabères C; Bordessoule D; Turlure P; Cony-Makhoul P; Hau F; Dazey B; Agape P; Reiffers J; Marit G
    Leuk Lymphoma; 2001 Apr; 41(3-4):285-96. PubMed ID: 11378541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation.
    Erard V; Guthrie KA; Riddell S; Boeckh M
    Haematologica; 2006 Oct; 91(10):1377-83. PubMed ID: 17018388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation.
    Ljungman P
    Curr Opin Hematol; 2014 Nov; 21(6):466-9. PubMed ID: 25159712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus Status and the Outcome of T Cell-Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.
    Verduyn Lunel FM; Raymakers R; van Dijk A; van der Wagen L; Minnema MC; Kuball J
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1883-1887. PubMed ID: 27470287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
    Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
    Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
    Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
    Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience.
    Febres-Aldana A; Khawaja F; Morado-Aramburo O; Shigle TL; Rondon G; Sassine J; Spallone A; Srinivasan K; Ramdial J; Alousi A; Champlin R; Chen G; Daher M; Rezvani K; Ariza-Heredia EJ; Shpall EJ; Chemaly RF
    Clin Microbiol Infect; 2024 Jun; 30(6):803-809. PubMed ID: 38460821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Factors for Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation in Malignancies: Proposal for Classification.
    Dziedzic M; Sadowska-Krawczenko I; Styczynski J
    Anticancer Res; 2017 Dec; 37(12):6551-6556. PubMed ID: 29187429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
    Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
    Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Schafhausen P; Jaburg N; Löliger C; Schäfer P; Hinke A; Zander AR
    Br J Haematol; 2001 Jun; 113(4):1060-71. PubMed ID: 11442503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.